No immediate stock-moving catalyst; traders should monitor for topline Phase 2 data in H2 2026. Phase 1 hsCRP reductions were strong, but Phase 2 proof-of-concept is still highly binary and carries clinical risk.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 16 $20.49entry
- T+1 · 5mo ago −2.44%α −1.19% · $19.99
- T+5 · 5mo ago +8.93%α +11.16% · $22.32
- T+20 · 4mo ago +11.18%α +10.98% · $22.78
- T+60 · 2mo ago −57.78%α −58.78% · $8.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) for cardiovascular risk reduction. Topline data expected H2 2026, a routine operational milestone with no financial or efficacy data disclosed.
Key Facts
- First participant dosed in Phase 2 trial QUELL-CV evaluating BGE-102
- Trial is randomized, double-blind, placebo-controlled, dose-ranging (30/60/90 mg QD) in ~160 participants
- Primary endpoint: percent change from baseline in hsCRP
- Topline data anticipated in second half of 2026
- Phase 1 data previously showed 86% median hsCRP reduction at 60 mg and 120 mg doses
Financial Impact
No financial data in release; $882M market cap, clinical-stage company with no revenue
Risk Factors
- Phase 2 may fail to replicate Phase 1 hsCRP reductions or show clinical benefit
- Competition from other NLRP3 inhibitors and anti-inflammatory cardiovascular therapies
- No approved products or revenue; capital needs for further development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312476 |
Track record
11 reports on BIOA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Viewing Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers